DK1817343T3 - Humane monoklone antistoffer mod humant IL-4 - Google Patents

Humane monoklone antistoffer mod humant IL-4

Info

Publication number: DK1817343T3
Authority: DK; Denmark
Prior art keywords: human; monoclonal antibodies; human monoclonal; antibodies; monoclonal
Prior art date: 2004-08-03

Application number

DK05769838.3T

Other languages

English (en)

Inventor

Herrera José M Carballido

Vries Jan E De

Christoph Schwaerzler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-03

Filing date

2005-08-02

Publication date

2014-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1817343(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-03 Priority claimed from GB0417301A external-priority patent/GB0417301D0/en

2004-08-03 Priority claimed from GB0417302A external-priority patent/GB0417302D0/en

2004-08-03 Priority claimed from GB0417306A external-priority patent/GB0417306D0/en

2004-08-03 Priority claimed from GB0417304A external-priority patent/GB0417304D0/en

2004-08-03 Priority claimed from GB0417303A external-priority patent/GB0417303D0/en

2004-08-03 Priority claimed from GB0417305A external-priority patent/GB0417305D0/en

2005-08-02 Application filed by Novartis Ag filed Critical Novartis Ag

2014-09-15 Application granted granted Critical

2014-09-15 Publication of DK1817343T3 publication Critical patent/DK1817343T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05769838.3T 2004-08-03 2005-08-02 Humane monoklone antistoffer mod humant IL-4 DK1817343T3 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB0417301A GB0417301D0 (en)	2004-08-03	2004-08-03	Organic compounds
GB0417302A GB0417302D0 (en)	2004-08-03	2004-08-03	Organic compounds
GB0417306A GB0417306D0 (en)	2004-08-03	2004-08-03	Organic compounds
GB0417304A GB0417304D0 (en)	2004-08-03	2004-08-03	Organic compounds
GB0417303A GB0417303D0 (en)	2004-08-03	2004-08-03	Organic compounds
GB0417305A GB0417305D0 (en)	2004-08-03	2004-08-03	Organic compounds
PCT/EP2005/008361 WO2006013087A1 (en)	2004-08-03	2005-08-02	Human monoclonal antibodies against human il-4

Publications (1)

Publication Number	Publication Date
DK1817343T3 true DK1817343T3 (da)	2014-09-15

Family

ID=35457817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05769838.3T DK1817343T3 (da)	2004-08-03	2005-08-02	Humane monoklone antistoffer mod humant IL-4

Country Status (28)

Country	Link
US (2)	US7740843B2 (da)
EP (2)	EP2327726A3 (da)
JP (1)	JP4808712B2 (da)
KR (1)	KR101245996B1 (da)
CN (1)	CN101001877B (da)
AR (1)	AR050044A1 (da)
AU (1)	AU2005268932B2 (da)
BR (1)	BRPI0514124B8 (da)
CA (1)	CA2574289C (da)
CY (1)	CY1115524T1 (da)
DK (1)	DK1817343T3 (da)
EC (1)	ECSP077222A (da)
ES (1)	ES2504415T3 (da)
HR (1)	HRP20140888T1 (da)
IL (1)	IL180789A (da)
MA (1)	MA28981B1 (da)
MX (1)	MX2007001342A (da)
MY (1)	MY141851A (da)
NO (1)	NO20070854L (da)
NZ (1)	NZ552637A (da)
PE (1)	PE20060560A1 (da)
PL (1)	PL1817343T3 (da)
PT (1)	PT1817343E (da)
SG (1)	SG155177A1 (da)
SI (1)	SI1817343T1 (da)
TN (1)	TNSN07036A1 (da)
TW (1)	TWI356828B (da)
WO (1)	WO2006013087A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8323645B2 (en) *	2005-03-24	2012-12-04	Millennium Pharmaceuticals, Inc.	Antibodies that bind OV064 and methods of use therefor
US8759490B2 (en)	2005-03-24	2014-06-24	Millennium Pharamaceuticals, Inc.	Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
US20110014117A1 (en) *	2007-06-28	2011-01-20	Schering Corporation	Anti-igf1r
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
RU2018108836A (ru)	2011-02-04	2019-03-14	Дженентек, Инк.	ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
BR122021009041B1 (pt)	2014-05-06	2022-11-29	Genentech, Inc	Métodos para a preparação de uma proteína heteromultimérica
WO2017196943A1 (en)	2016-05-10	2017-11-16	Minneapolis Medical Research Foundation	Cytokine signaling immunomodulators and methods
CN108409860B (zh) *	2017-02-10	2021-10-15	三生国健药业（上海）股份有限公司	抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
EP3655961A4 (en) *	2017-07-17	2021-09-01	Massachusetts Institute of Technology	HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
MX2021010560A (es)	2019-03-06	2021-11-12	Regeneron Pharma	Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3132587A1 (en)	2019-03-21	2020-09-24	Regeneron Pharmaceuticals, Inc.	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN114957472B (zh) *	2020-06-22	2023-10-31	南京融捷康生物科技有限公司	抗IL-4Rα的单域抗体以及应用和药物
US20230220089A1 (en)	2021-12-30	2023-07-13	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CN118388645B (zh) *	2024-05-17	2024-11-22	康立泰生物医药(青岛)有限公司	一种抗人白介素4抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5041381A (en) *	1986-07-03	1991-08-20	Schering Corporation	Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE68908431T2 (de)	1988-02-02	1993-12-23	Schering Biotech Corp	Methode zur Verminderung der Immunglobulin-E-Reaktion.
ATE136906T1 (de) *	1989-12-20	1996-05-15	Schering Corp	Antikörperantagonisten gegen humanes interleukin- 4
CA2130436C (en)	1992-02-19	2001-04-10	John S. Abrams	Cloning and expression of humanized monoclonal antibodies against human interleukin-4
RU2120802C1 (ru)	1992-08-20	1998-10-27	Шеринг Корпорейшн	Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
WO1995007301A1 (en)	1993-09-07	1995-03-16	Smithkline Beecham Corporation	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5914110A (en) *	1993-09-07	1999-06-22	Smithkline Beecham Corporation	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) *	1994-03-10	1997-01-28	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) *	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) *	2000-05-26	2002-01-03	Pluenneke John D.	Use of interleukin-4 antagonists and compositions thereof
NZ541050A (en)	2002-12-16	2010-06-25	Genmab As	Human monoclonal antibodies against interleukin 8 (IL-8)
FR2859725B1 (fr) *	2003-09-16	2006-03-10	Neovacs	Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

2005
- 2005-08-01 PE PE2005000884A patent/PE20060560A1/es not_active Application Discontinuation
- 2005-08-01 AR ARP050103199A patent/AR050044A1/es not_active Application Discontinuation
- 2005-08-02 ES ES05769838.3T patent/ES2504415T3/es not_active Expired - Lifetime
- 2005-08-02 JP JP2007524263A patent/JP4808712B2/ja not_active Expired - Fee Related
- 2005-08-02 WO PCT/EP2005/008361 patent/WO2006013087A1/en not_active Ceased
- 2005-08-02 BR BRPI0514124A patent/BRPI0514124B8/pt not_active IP Right Cessation
- 2005-08-02 SG SG200905152-5A patent/SG155177A1/en unknown
- 2005-08-02 CN CN2005800260794A patent/CN101001877B/zh not_active Expired - Fee Related
- 2005-08-02 HR HRP20140888TT patent/HRP20140888T1/hr unknown
- 2005-08-02 AU AU2005268932A patent/AU2005268932B2/en not_active Ceased
- 2005-08-02 NZ NZ552637A patent/NZ552637A/en not_active IP Right Cessation
- 2005-08-02 CA CA2574289A patent/CA2574289C/en not_active Expired - Fee Related
- 2005-08-02 MX MX2007001342A patent/MX2007001342A/es active IP Right Grant
- 2005-08-02 EP EP10180854A patent/EP2327726A3/en not_active Withdrawn
- 2005-08-02 TW TW094126210A patent/TWI356828B/zh not_active IP Right Cessation
- 2005-08-02 EP EP05769838.3A patent/EP1817343B1/en not_active Expired - Lifetime
- 2005-08-02 KR KR1020077002715A patent/KR101245996B1/ko not_active Expired - Fee Related
- 2005-08-02 SI SI200531872T patent/SI1817343T1/sl unknown
- 2005-08-02 US US11/632,939 patent/US7740843B2/en not_active Expired - Fee Related
- 2005-08-02 PL PL05769838T patent/PL1817343T3/pl unknown
- 2005-08-02 PT PT57698383T patent/PT1817343E/pt unknown
- 2005-08-02 MY MYPI20053585A patent/MY141851A/en unknown
- 2005-08-02 DK DK05769838.3T patent/DK1817343T3/da active
2007
- 2007-01-18 IL IL180789A patent/IL180789A/en not_active IP Right Cessation
- 2007-02-02 TN TNP2007000036A patent/TNSN07036A1/en unknown
- 2007-02-02 EC EC2007007222A patent/ECSP077222A/es unknown
- 2007-02-14 NO NO20070854A patent/NO20070854L/no not_active Application Discontinuation
- 2007-02-22 MA MA29708A patent/MA28981B1/fr unknown
2010
- 2010-04-15 US US12/760,891 patent/US20100254993A1/en not_active Abandoned
2014
- 2014-09-05 CY CY20141100716T patent/CY1115524T1/el unknown

Also Published As

Publication number	Publication date
TWI356828B (en)	2012-01-21
SG155177A1 (en)	2009-09-30
US20080241160A1 (en)	2008-10-02
JP4808712B2 (ja)	2011-11-02
BRPI0514124A (pt)	2008-05-27
TW200617024A (en)	2006-06-01
EP1817343B1 (en)	2014-06-25
WO2006013087A1 (en)	2006-02-09
CA2574289C (en)	2014-09-16
US7740843B2 (en)	2010-06-22
AR050044A1 (es)	2006-09-20
EP2327726A2 (en)	2011-06-01
PL1817343T3 (pl)	2014-11-28
US20100254993A1 (en)	2010-10-07
CA2574289A1 (en)	2006-02-09
EP2327726A3 (en)	2012-07-11
HRP20140888T1 (hr)	2014-10-24
NZ552637A (en)	2010-02-26
CN101001877B (zh)	2012-09-26
JP2008507985A (ja)	2008-03-21
PT1817343E (pt)	2014-09-09
CY1115524T1 (el)	2017-01-04
SI1817343T1 (sl)	2014-09-30
WO2006013087A8 (en)	2007-03-01
IL180789A (en)	2017-01-31
BRPI0514124B8 (pt)	2021-05-25
EP1817343A1 (en)	2007-08-15
ES2504415T3 (es)	2014-10-08
CN101001877A (zh)	2007-07-18
NO20070854L (no)	2007-04-24
AU2005268932B2 (en)	2009-06-25
MA28981B1 (fr)	2007-11-01
AU2005268932A1 (en)	2006-02-09
KR101245996B1 (ko)	2013-03-20
KR20070047299A (ko)	2007-05-04
MY141851A (en)	2010-07-16
TNSN07036A1 (en)	2008-06-02
HK1109158A1 (en)	2008-05-30
IL180789A0 (en)	2007-06-03
MX2007001342A (es)	2007-04-02
BRPI0514124B1 (pt)	2017-01-31
PE20060560A1 (es)	2006-06-27
ECSP077222A (es)	2007-03-29

Publication	Publication Date	Title
ATE484525T1 (de)	2010-10-15	Modifizierte humane igf-1r antikörper
NO20052889D0 (no)	2005-06-14	Humane monoklonale antistoffer mot CD25
CY2016016I1 (el)	2016-12-14	Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
DK1960434T3 (da)	2012-10-15	Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
DK2327423T3 (da)	2019-12-16	Humane antistoffer mod humant interleukin-22 (IL-22)
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
DK2115003T3 (da)	2012-07-09	Humane antistoffer mod human delta-lignende ligand 4
DK1844074T3 (da)	2013-07-15	Humane antistoffer og proteiner
ATE465180T1 (de)	2010-05-15	Therapeutische anti-igfr1-antikörper- kombinationen
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
DK2177537T3 (da)	2011-12-12	Antistoffer til MAdCAM
CY2016035I2 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
RU2426741C3 (ru)	2017-11-15	Антагонистические антитела к il-17
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
PL372662A1 (pl)	2005-07-25	Przeciwciała wobec alfav beta6
HRP20220755T3 (hr)	2022-09-02	Anti-gm-csf antitijela i njihova uporaba
HRP20160875T1 (hr)	2016-09-23	Humana anti-b7rp1 neutralizirajuća antitijela
IS3021B (is)	2020-04-15	Mótefni gegn M-CSF
DK3156422T3 (da)	2021-11-22	Humane højaffinitetsantistoffer mod pcsk9
DK1737891T3 (da)	2013-03-25	Anti-p-selectin-antistoffer
DK2292663T3 (da)	2013-11-04	Antagonistiske human-let-specifikke, humane monoklonale antistoffer
CY2013046I2 (el)	2015-11-04	Καινοτομος χρηση των αντισωματων αντι il-1bhta
DK1817343T3 (da)	2014-09-15	Humane monoklone antistoffer mod humant IL-4
DK1809660T3 (da)	2014-10-20	Thymus-specifikt protein
EP1826218A4 (en)	2009-11-25	ANTI-HUMAN BAFF ANTIBODIES